eTable. Dose adjustment, need of dose adjustment and dialyzability of anticancer drugs in chronic kidney failure and dialysis dependence (according to 18–20).
| Substance* | Need for dose reduction in chronic kidney disease | Need for dose adjustment after dialysis/standard dose before hemodialysis |
| 177Lu-PSMA-617 | No (GFR 30 mL/min), GFR < 30 ml/min: not stated | Not stated |
| 5-Fluoruracil | No | No, if necessary, infusion during HD |
| Abemaciclib | No | No |
| Abiraterone acetate | No | No |
| Acalabrutinib | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not stated | Not stated |
| Afatinib | Yes ifi GFR <30 ml/min) | Yes, if necessary, dose prior to HD |
| Aflibercept | No | No |
| Alectinib | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not stated | Not stated |
| Amivantamab | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not stated | Not stated |
| Amsacrine | Yes (if crea >2 mg/dL) | Not stated |
| Anagrelide | No | No |
| Anastrozol | No | No |
| Apalutamide | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not stated | Not stated |
| Arsenic trioxide | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not stated | Not stated |
| Asciminib | No (GFR ≥ 15 mL/min), GFR <15 ml/min: not stated | Not stated |
| Atezolizumab | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not stated | Not stated |
| Avelumab | No (GFR ≥ 15 mL/min), GFR <15 ml/min: not stated | Not stated |
| Axicabtagene ciloleucel | Not stated | Not stated |
| Axitinib | No (GFR ≥ 15 mL/min), GFR <15 ml/min: not stated | Not stated |
| Azacitidine | No | No |
| Belantamab mafodotin | No (GFR ≥ 15 mL/min), GFR <15 ml/min: not stated | Not stated |
| Belzutifan | No (GFR ≥ 15 mL/min), GFR <15 ml/min: not stated | Not stated |
| Bendamustine | No | No |
| Bevacizumab | No | No |
| Bicalutamide | No | No |
| Binimetinib | No | No |
| Bleomycin | Yes (if GFR <50 ml/min) | Yes, or dose prior to HD |
| Blinatumomab | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not stated | Not stated |
| Bortezomib | No | No |
| Bosutinib | Yes (if GFR <50 ml/min) | Not stated |
| Brentuximab vedotin | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not recommended | Not stated |
| Brexucabtagene autoleucel | Not stated | Not stated |
| Brigatinib | Yes (if GFR <30 ml/min) | Not stated |
| Cabazitaxel | No | Not stated |
| Cabozantinib | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not stated | Not stated |
| Capecitabine | Yes (if GFR <50 ml/min) | Not recommended, or dose prior to HD |
| Capmatinib | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not stated | Not stated |
| Carboplatin | Yes (if GFR <60 ml/min) | Yes, or dose prior to HD |
| Carfilzomib | No | No |
| Carmustine | Yes (if GFR <60 ml/min), gfr <30 ml/min: not recommended | Not recommended |
| CCNU (lomustine) | Yes (if GFR <60 ml/min), gfr <30 ml/min: not recommended | Not recommended |
| Cemiplimab | No (GFR ≥ 21 mL/min), GFR <21 ml/min: not stated | Not stated |
| Ceritinib | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not stated | Not stated |
| Cetuximab | No | No |
| Chlorambucil | Yes (if GFR <50 ml/min) | Yes |
| Ciltacabtagene autoleucel | Not stated | Not stated |
| Cisplatin | Yes (if GFR <60 ml/min), gfr <40 ml/min: not recommended | Yes, or dose prior to HD (palliative use not recommended) |
| Cladribine | Yes (if GFR <50 ml/min) | Yes |
| CPX-351 | No (GFR ≥ 15 mL/min), GFR <15 ml/min: not stated | Not stated |
| Cobimetinib | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not stated | Not stated |
| Crizotinib | Yes (if GFR <30 ml/min) | Not stated |
| Cyclophosphamide | Yes (if GFR <10 ml/min) | Yes, or dose prior to HD |
| Cytarabine | Yes (if GFR <60 ml/min, not required with low-dose protocol) | Yes, or dose after HD |
| Dabrafenib | No (GFR ≥ 15 mL/min), GFR <15 ml/min: not stated | Not stated |
| Dacarbazin | Yes (if GFR <30 ml/min) | Yes |
| Dacomitinib | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not stated | Not stated |
| Daratumumab | No | No |
| Darolutamide | Yes (if GFR <30 ml/min) | Not stated |
| Daunorubicin | Yes (if GFR <50 ml/min) | Yes |
| Decitabine | No | Not stated |
| Docetaxel | No | No, or dose prior to HD |
| Dostarlimab | No | No |
| Doxorubicin | No | No, if necessary, consider low initial dose |
| Durvalumab | No (GFR ≥ 15 mL/min), GFR <15 ml/min: not stated | Not stated |
| Elotuzumab | No | No |
| Enasidenib | No | No |
| Encorafenib | No | No |
| Enfortumab vedotin | No | Not stated |
| Entrectinib | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not stated | Not stated |
| Enzalutamide | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not stated | Not stated |
| Epcoritamab | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not stated | Not stated |
| Epirubicin | No | No |
| Eribulin | Yes (if GFR <50 ml/min) | Yes |
| Erlotinib | No | If necessary, dose prior to HD |
| Etoposide | Yes (if GFR <50 ml/min) | Yes (administration before or after dialysis) |
| Everolimus | No | No |
| Fludarabine | Yes (if GFR <70 ml/min) | Yes, or dose prior to HD |
| Fruquintinib | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not stated | Not stated |
| Gefitinib | No | No |
| Gemcitabine | Yes (if GFR <30 ml/min) | No, or dose prior to HD |
| Gemtuzumab ozogamicin | No (GFR ≥ 15 mL/min), GFR <15 ml/min: not stated | Not stated |
| Gilteritinib | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not stated | Not stated |
| Glasdegib | No (GFR ≥ 15 mL/min), GFR <15 ml/min: not stated | Not stated |
| Glofitamab | No (GFR ≥ 15 mL/min), GFR <15 ml/min: not stated | Not stated |
| Ibrutinib | No | No |
| Idelalisib | No (GFR ≥ 15 mL/min), GFR <15 ml/min: not stated | Not stated |
| Ifosfamid | Yes (if GFR <50 ml/min) | Not recommended, or dose prior to HD |
| Inotuzumab ozogamicin | No | No |
| Ipilimumab | No (GFR ≥ 15 mL/min), GFR <15 ml/min: not stated | Not stated |
| Irinotecan | Yes (consider if GFR <50 ml/min) | Yes, or dose prior to HD |
| Ivosidenib | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not stated | Not stated |
| Ixazomib | Yes (if GFR <30 ml/min) | Yes |
| Iodine-131 | Yes | Yes, or dose prior to HD |
| Larotrectinib | No | No |
| Lenalidomide | Yes (if GFR <60 ml/min) | Yes, or dose prior to HD |
| Lenvatinib | Yes | Not stated |
| Letrozole | No | No |
| Lisocabtagene maraleucel | Not stated | Not stated |
| Loncastuximab tesirine | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not stated | Not stated |
| Lorlatinib | Yes (if GFR <30 ml/min) | Not stated |
| Luspatercept | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not stated | Not stated |
| Melphalan | Yes (if GFR <60 ml/min) | Yes, or dose prior to HD |
| Methotrexate | Yes (if GFR <50 ml/min) | Avoid use, or dose prior to HD |
| Midostaurin | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not stated | Not stated |
| Mitomycin C | No (not recommended if GFR <30 ml/min) | Not recommended |
| Mitotane | Not recommended with severe chronic kidney disease | Not stated |
| Moxetumomab pasudotox | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not recommended | Not stated |
| Nab-Paclitaxel | No | No |
| Necitumumab | No | No |
| Nintedanib | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not stated | Not stated |
| Niraparib | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not stated | Not stated |
| Nivolumab | No | No |
| Obinutuzumab | No | No |
| Octreotide | No | No |
| Olaratumab | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not stated | Not stated |
| Olaparib | Yes (if GFR <50 ml/min) | Not stated |
| Osimertinib | No | No |
| Oxaliplatin | Yes (if GFR <30 ml/min) | Avoid use, or dose prior to HD |
| Paclitaxel | No | No |
| Palbociclib | No | No |
| Panobinostat | No | No |
| Panitumumab | No | No |
| Pazopanib | No | No |
| Pembrolizumab | No | No |
| Pemetrexed | No (not recommended if GFR <45 ml/min) | Avoid use, or dose prior to HD |
| Pemigatinib | Yes (if GFR <30 ml/min) | No |
| Pentostatin | Yes (if GFR <60 ml/min) | Not stated |
| Pertuzumab | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not stated | Not stated |
| Pomalidomide | Yes (if GFR <45 ml/min) | Yes |
| Ponatinib | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not stated | Not stated |
| Radium-223 | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not stated | Not stated |
| Ramucirumab | No (GFR ≥ 15 mL/min), GFR <15 ml/min: not stated | Not stated |
| Regorafenib | No (GFR ≥ 15 mL/min), GFR <15 ml/min: not stated | Not stated |
| Relugolix | No (GFR ≥ 15 mL/min), GFR <15 ml/min: not stated | Not stated |
| Ribociclib | Yes (if GFR <30 ml/min) | Not stated |
| Rituximab | No | No |
| Rucaparib | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not stated | Not stated |
| Ruxolitinib | Yes (if GFR <60 ml/min) | Yes |
| Sacituzumab govitecan | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not stated | Not stated |
| Selinexor | No (GFR ≥ 15 mL/min), GFR <15 ml/min: not stated | Not stated |
| Selpercatinib | No (GFR ≥ 15 mL/min), GFR <15 ml/min: not stated | Not stated |
| Siltuximab | No (GFR ≥ 15 mL/min), GFR <15 ml/min: not stated | Not stated |
| Sonidegib | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not stated | No |
| Sorafenib | Yes (if GFR <40 ml/min) | Yes |
| Sotorasib | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not stated | Not stated |
| Streptozotocin | Yes (if GFR <50 ml/min) | Not stated |
| Sunitinib | No | No, or dose prior to HD |
| Talazoparib | Yes (if GFR <60 ml/min) | Not stated |
| Talquetamab | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not stated | Not stated |
| Tamoxifen | No | No |
| Tebentafusp | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not stated | Not stated |
| Teclistamab | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not stated | Not stated |
| Tegafur uracil | Yes (if GFR <50 ml/min) | No, or dose prior to HD |
| Temozolomide | No (GFR ≥ 36 mL/min), GFR <36 ml/min: not stated | Not stated |
| Tisagenlecleucel | keine Angabe | Not stated |
| Tivozanib | No (GFR ≥ 15 mL/min), GFR <15 ml/min: not stated | Not stated |
| Topotecan | Yes (if GFR <40 ml/min) | Avoid use, or dose prior to HD |
| Trabectedin | No | No |
| Trametinib | No (GFR ≥ 15 mL/min), GFR <15 ml/min: not stated | Not stated |
| Trastuzumab | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not stated | Not stated |
| Trastuzumab deruxtecan | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not stated | Not stated |
| Trastuzumab emtansin | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not stated | Not stated |
| Tremelimumab | No (GFR ≥ 15 mL/min), GFR <15 ml/min: not stated | Not stated |
| Treosulfan | No, not recommended with severe chronic kidney disease | Not stated |
| Trifluridine tirapicil | Yes (if GFR <30 ml/min) | Use not recommended |
| Tucatinib | No (GFR ≥ 30 mL/min), GFR <30 ml/min: not stated | Not stated |
| Vandetanib | Yes (if GFR <50 ml/min) | Not stated |
| Vemurafenib | No | No |
| Venetoclax | No | No |
| Vinblastine | No | No |
| Vincristine | No | No |
| Vinflunine | Yes (if GFR <60 ml/min) | Not stated |
| Vismodegib | No | No |
| Zanubrutinib | No (GFR ≥ 15 mL/min), GFR <15 ml/min: not stated | Not stated |
* For a patient-specific treatment decision, additional searches by the treating physicians are required. 177Lu-PSMA-617, lutetium (177Lu) vipivotide tetraxetan; GFR, glomerular filtration rate; HD, hemodialysis; crea, creatinine